“The current condition has exposed some structural weaknesses from the EU’s medicines offer chain as well as a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides mentioned. She advised that supply chain troubles be resolved within an EU pharmaceutical strategy predicted to be launched by the end of https://active-pharmaceutical-ing36401.blogerus.com/52616604/the-2-minute-rule-for-api-in-pharmaceutical-manufacturing